New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 28, 2012
10:36 EDTTEVA, MYLMylan launches generic Nordette 28 tablets
Mylan (MYL) announced that its partner Famy Care Ltd. has received final approval from the FDA for its Abbreviated New Drug Application for Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg. This product is the generic version of Teva Branded Pharmaceutical Products' (TEVA) Nordette 28 Tablets, which are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. The product will be distributed in the U.S. by Mylan Pharmaceuticals Inc., and the company is shipping product immediately.
News For MYL;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 8, 2015
15:27 EDTMYLMylan hasn't made compelling case for Perrigo adding value, says BMO Capital
Subscribe for More Information
15:16 EDTMYLPerrigo not likely interested in a Mylan deal, says BMO Capital
14:23 EDTMYL, TEVAAdditional bidders for Perrigo could emerge after Mylan offer, says Stifel
Subscribe for More Information
13:07 EDTTEVA, MYLMylan bid for Perrigo makes strategic sense, says JPMorgan
Subscribe for More Information
13:03 EDTMYLPerrigo says board will meet to discuss Mylan proposal
Subscribe for More Information
12:37 EDTTEVATeva downgraded to Hold from Buy at Standpoint Research
Subscribe for More Information
12:17 EDTMYLOn The Fly: Midday Wrap
Subscribe for More Information
11:51 EDTMYLPerrigo calls active on Mylan proposal to acquire for $205 per share
Subscribe for More Information
11:45 EDTMYLMylan volatility up after proposes to acquire Perrigo for $205 per share
Subscribe for More Information
11:40 EDTMYLPerrigo up $47.10 to $211.81, trading above Mylan's $205/share proposal
Subscribe for More Information
11:35 EDTMYLGeneric drug maker Akorn up 4% to $49.80 after Myla offers to buy Perrigo
Subscribe for More Information
11:34 EDTMYLGeneric drug maker Akorn up 4% to $49.80 after Myla offers to buy Perrigo
11:32 EDTMYLMylan proposes to acquire Perrigo for $205 per share
Subscribe for More Information
11:31 EDTMYLPerrigo halted for volatility after jumping 7% to $176.42
Subscribe for More Information
11:29 EDTMYLMylan proposes to acquire Perrigo for $205 per share
Subscribe for More Information
07:16 EDTTEVA, MYLMylan one of the cheapest names in Specialty Pharma, says JPMorgan
Subscribe for More Information
April 7, 2015
15:24 EDTTEVATeva price target raised to $75 from $64 at BMO Capital
BMO Capital raised its EPS estimates for Teva (TEVA) and increased its price target on the stock to $75 from $64 on account of the expected launch of a treatment for chorea associated with Huntington’s disease in 3Q16 and a launch of a tardive dyskinesia drug in 3Q17 following the company's deal to buy Auspex (ASPX). The firm maintains its Outperform rating on Teva shares.
10:19 EDTMYLHigh option volume stocks
Subscribe for More Information
07:32 EDTMYLMylan launches Norethindrone and Ethinyl Estradiol Tablets in U.S.
Subscribe for More Information
April 6, 2015
05:56 EDTTEVATeva battles possible generic Copaxone competitors, Globes reports
A citizen's petition has been filed by Teva with the FDA against possible generic competition to its MS treatment Copaxone beginning in September, Globes reports. The FDA has previously ruled that it was "too early" to discuss the matter. Reference Link
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use